Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
暂无分享,去创建一个
U. Nielsen | G. Adams | L. Weiner | J. Marks
[1] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[2] U. Nielsen,et al. Expression of single-chain Fv-Fc fusions in Pichia pastoris. , 2001, Journal of immunological methods.
[3] G W Beresford,et al. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] L. Zardi,et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.
[5] S. Batra,et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. , 2002, Current opinion in biotechnology.
[6] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[7] G. Adams,et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.
[8] W. Anderson,et al. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. , 1997, Journal of immunological methods.
[9] G. Adams,et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.
[10] R. Hawkins,et al. Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.
[11] L E Williams,et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.
[12] P B Laub,et al. NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data. , 1996, Journal of pharmaceutical sciences.
[13] L E Williams,et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.
[14] J. Huston,et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.
[15] R. Williams,et al. Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.
[16] M. Whitlow,et al. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. , 1994, Protein engineering.
[17] K. Lamborn,et al. The biologic window for chimeric l6 radioimmunotherapy , 1994, Cancer.
[18] L L Houston,et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.
[19] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[20] R K Jain,et al. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. , 1992, Cancer research.
[21] T. Yokota,et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.
[22] A. Plückthun,et al. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. , 1992, Biochemistry.
[23] T. Yokota,et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.
[24] K. D. Hardman,et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.
[25] R K Jain,et al. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.
[26] K. Fujimori,et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.
[27] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[28] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[29] D M Crothers,et al. The influence of polyvalency on the binding properties of antibodies. , 1972, Immunochemistry.